October 20, 2016 07:25 AM EDT

Rigel’s 2nd PhIII for fostamatinib scuttled by a single placebo response, shares crater

John Carroll

Editor & Founder

Rigel Pharmaceuticals continues to be plagued by a low response rate in its big Phase III program for fostamatinib. But unlike its first late-stage data …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Rigel’s 2nd PhIII for fostamatinib scuttled by a single placebo response, shares crater

John Carroll

Editor & Founder

Sign up to read this article for free.

Novartis to cut 139 jobs in NJ as part of commercial refocus

Applied Therapeutics' rare disease drug gets a CRL

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway

Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Rigel’s 2nd PhI­II for fos­ta­ma­tinib scut­tled by a sin­gle place­bo re­sponse, shares crater

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Rigel’s 2nd PhIII for fostamatinib scuttled by a single placebo response, shares crater

Novartis to cut 139 jobs in NJ as part of commercial refocus

Applied Therapeutics' rare disease drug gets a CRL

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway

Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy